Sprint Bioscience AB (SPRINT) - Total Liabilities

Latest as of March 2026: Skr12.69 Million SEK ≈ $1.37 Million USD

Based on the latest financial reports, Sprint Bioscience AB (SPRINT) has total liabilities worth Skr12.69 Million SEK (≈ $1.37 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check SPRINT asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Sprint Bioscience AB - Total Liabilities Trend (2011–2025)

This chart illustrates how Sprint Bioscience AB's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Sprint Bioscience AB.

Sprint Bioscience AB Competitors by Total Liabilities

The table below lists competitors of Sprint Bioscience AB ranked by their total liabilities.

Company	Country	Total Liabilities
Navamedic ASA OL:NAVA	Norway	Nkr350.53 Million
Modi Rubber Limited NSE:MODIRUBBER	India	Rs938.57 Million
A-Tech Solution Co. Ltd KQ:071670	Korea	₩221.67 Billion
Bubang Co. Ltd KQ:014470	Korea	₩81.19 Billion
Panorama Sentrawisata Tbk JK:PANR	Indonesia	Rp724.87 Billion
UCAL Limited NSE:UCAL	India	Rs4.93 Billion
Microequities Asset Management Group Ltd AU:MAM	Australia	AU$7.06 Million
Eurospan Holdings Bhd KLSE:7094	Malaysia	RM31.91 Million

Liability Composition Analysis (2011–2025)

This chart breaks down Sprint Bioscience AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Sprint Bioscience AB (SPRINT) balance sheet quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	9.10	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.12	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.11	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Sprint Bioscience AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Sprint Bioscience AB (2011–2025)

The table below shows the annual total liabilities of Sprint Bioscience AB from 2011 to 2025.

Year	Total Liabilities	Change
2025-12-31	Skr17.48 Million ≈ $1.88 Million	-46.67%
2024-12-31	Skr32.78 Million ≈ $3.53 Million	-5.26%
2023-12-31	Skr34.60 Million ≈ $3.72 Million	+274.73%
2022-12-31	Skr9.23 Million ≈ $993.73K	+6.35%
2021-12-31	Skr8.68 Million ≈ $934.43K	-64.20%
2020-12-31	Skr24.25 Million ≈ $2.61 Million	+194.82%
2019-12-31	Skr8.23 Million ≈ $885.36K	-62.68%
2018-12-31	Skr22.05 Million ≈ $2.37 Million	+198.09%
2017-12-31	Skr7.40 Million ≈ $795.93K	-64.83%
2016-12-31	Skr21.03 Million ≈ $2.26 Million	-18.54%
2015-12-31	Skr25.81 Million ≈ $2.78 Million	+434.79%
2014-12-31	Skr4.83 Million ≈ $519.44K	+17.47%
2013-12-31	Skr4.11 Million ≈ $442.19K	+28.24%
2012-12-31	Skr3.20 Million ≈ $344.81K	+329.45%
2011-12-31	Skr746.09K ≈ $80.29K	--

About Sprint Bioscience AB

ST:SPRINT Sweden Biotechnology

Market Cap

$33.50 Million

Skr311.27 Million SEK

Market Cap Rank

#23474 Global

#446 in Sweden

Share Price

Skr2.95

Change (1 day)

+1.72%

52-Week Range

Skr0.56 - Skr4.49

All Time High

Skr47.75